<DOC>
	<DOCNO>NCT02932150</DOCNO>
	<brief_summary>The primary objective study follow : Part A : To evaluate steady state pharmacokinetics ( PK ) tenofovir alafenamide ( TAF ) confirm dose TAF 25 mg tablet give daily treatment-naive treatment-experienced adolescent ( age 12 &lt; 18 year ) chronic hepatitis B ( CHB ) Part B : To evaluate safety , tolerability , antiviral activity ( HBV DNA &lt; 20 IU/mL ) TAF 25 mg daily versus placebo Week 24 treatment-naive treatment-experienced adolescent CHB .</brief_summary>
	<brief_title>Tenofovir Alafenamide ( TAF ) Adolescents With Chronic Hepatitis B Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Inclusion criterion : Males nonpregnant , nonlactating female Weight Screening : ≥ 35 kg ( 77 lb ) Able swallow oral tablet Willing able provide write informed consent/assent ( child parent/legal guardian ) Documented evidence CHB ( eg , HBsAgpositive ≥ 6 month ) Treatmentnaive treatmentexperienced eligible enrollment . Estimated creatinine clearance ( CLCr ) ≥ 80 mL/min/1.73m^2 ( use Schwartz formula ) Normal ECG Key Exclusion criterion : Females breastfeed Males female reproductive potential unwilling use `` effective '' , protocolspecified method ( ) contraception study . Coinfection hepatitis C virus ( HCV ) , HIV , hepatitis D virus ( HDV ) Evidence hepatocellular carcinoma Any history , current evidence , clinical hepatic decompensation Abnormal hematological biochemical parameter Received solid organ bone marrow transplant Currently receive therapy immunomodulators ( eg , corticosteroid ) , immunosuppressant Significant renal , cardiovascular , pulmonary , neurological disease opinion Investigator Malignancy within 5 year prior screen . Individuals evaluation possible malignancy eligible . Current alcohol substance abuse judge investigator potentially interfere subject compliance . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CHB</keyword>
	<keyword>HBV</keyword>
</DOC>